List View

By /

Clear

Displaying 676 - 700 of 2,995

Squamous NSCLC and Small Cell Lung Cancer Update

Squamous NSCLC and Small Cell Lung Cancer Update

Triple Negative Breast Cancer: Optimal Neoadjuvant Therapy and New Directions

Triple Negative Breast Cancer: Optimal Neoadjuvant Therapy and New Directions

Updates on FL and CLL from the ASH 2021 Meeting

Updates on FL and CLL from the ASH 2021 Meeting

Updates in Targeted Therapy and Percision Oncology

Updates in Targeted Therapy and Percision Oncology

Lung Adenocarcinoma Updates

Lung Adenocarcinoma Updates

Roundtable Discussion

Roundtable Discussion

Updates in Renal Cell Carcinoma

Updates in Renal Cell Carcinoma

Toxicity Management of Novel Agents in Lung Cancer

Toxicity Management of Novel Agents in Lung Cancer

Overview of Current Cancer Screenings

Overview of Current Cancer Screenings

Integrative Oncology: Treatment Approaches for Stress in Cancer Patients and Survivors

Integrative Oncology: Treatment Approaches for Stress in Cancer Patients and Survivors

Novel Innovations in Proton Therapy

Novel Innovations in Proton Therapy

Cancer Survivorship: A Long-Term Journey

Cancer Survivorship: A Long-Term Journey

Targeted Therapy for HNSCC and Thyroid Cancer

Targeted Therapy for HNSCC and Thyroid Cancer

Soft Tissue Sarcoma

Soft Tissue Sarcoma

Updates in Kidney and Bladder Cancers

Updates in Kidney and Bladder Cancers

Immunotherapy for Melanoma

Immunotherapy for Melanoma

Immunotherapies in Gynecologic Malignancies

Immunotherapies in Gynecologic Malignancies

Dealing with EGFRex19del & L858R, ALK, and K-RasG12C Genetic Aberrations

Dealing with EGFRex19del & L858R, ALK, and K-RasG12C Genetic Aberrations

Uncommon Mutations/ Fusions: EGFRex20, RET, MET, HER2, NRG1

Uncommon Mutations/ Fusions: EGFRex20, RET, MET, HER2, NRG1

Neo-Adjuvant and Adjuvant Immunotherapy for Non-Small Cell Lung Cancer

Neo-Adjuvant and Adjuvant Immunotherapy for Non-Small Cell Lung Cancer

How to Choose Front- Line Therapy for Metastatic NSCLC Without Driver Mutations

How to Choose Front- Line Therapy for Metastatic NSCLC Without Driver Mutations

Stage III NSCLC: Beyond the PACIFIC/ Novel Approaches

Stage III NSCLC: Beyond the PACIFIC/ Novel Approaches

Plasma Genotyping in NSCLC: Layering in the Liquid and Future Applications

Plasma Genotyping in NSCLC: Layering in the Liquid and Future Applications

Predictive and Prognostic Biomarkers for IO: Value of TMB, MSI, PD-L1, and Others in Liquid and Solid Tumor Specimens

Predictive and Prognostic Biomarkers for IO: Value of TMB, MSI, PD-L1, and Others in Liquid and Solid Tumor Specimens

Metastatic Colorectal Cancer Therapy

Metastatic Colorectal Cancer Therapy